


THE FACTS ON EPIPEN COSTS

EpiPen price increases outpace patient cost sharing

- ➔ Mylan increased its list price from \$100 in 2009 to over \$600 in 2016
- ➔ Over the same period, fixed patient copays increased from \$27 to \$31, while coinsurance rates held steady at approximately 25–27%
- ➔ In fact, the average patient cost share for EpiPens — including both copays and coinsurance — decreased from 26% of the list price in 2009, to 11% in 2016




Note: Patient cost share is average for a preferred brand drug

Price concessions negotiated by PBMs significantly reduce costs to the health plan sponsor



Of the \$409 net EpiPen cost, who pays and who receives the money?



Source: Visante estimates prepared for the Pharmaceutical Care Management Association. (2016).